생체내 세포 치료 시장 규모, 점유율, 동향 분석 보고서 : 치료용 세포 유형별, 치료 용도별, 생체내 세포 공학별, 전달 방법별, 지역별 및 부문별 예측(2026-2033년)

In Vivo Cell Therapy Market Summary

The global in vivo cell therapy market size was valued at USD 229.2 million in 2025 and is projected to grow from USD 340.7 million in 2026 to USD 5726.3 million by 2033, at a CAGR of 49.6% from 2026 to 2033. North America dominated the global market, accounting for the largest revenue share of 55.9% in 2025. The investment in vivo cell therapy development, advances in targeted delivery technologies, and growing adoption of programmable cell-engineering approaches for precision medicine.

Global In Vivo Cell Therapy Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the global in vivo cell therapy industry on the basis of therapeutic cell type, therapeutic application, in vivo cell-engineering, delivery modality, and region

• Therapeutic Cell Type Outlook (Revenue, USD Million, 2021 - 2033)
• T Cells
• NK Cells
• Myeloid Cells
• Other Immune Cells
• Therapeutic Application Outlook (Revenue, USD Million, 2021 - 2033)
• Hematological Malignancies
• Solid Tumors
• Autoimmune Disease
• Infectious Disease
• Other Therapeutic Applications
• In Vivo Cell- Engineering Outlook (Revenue, USD Million, 2021 - 2033)
• Receptor Engineering
• Gene Editing & Gene Modification
• Transient Genetic Programming
• Other Cell -Engineering Approaches
• Delivery Modality Outlook (Revenue, USD Million, 2021 - 2033)
• Viral Vector-based
• Lipid Nanoparticle-based
• Other Non-viral Delivery System
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Therapeutic Cell Type
    • 1.1.1.2. Therapeutic Application
    • 1.1.1.3. In Vivo Cell-Engineering
    • 1.1.1.4. Delivery Modality
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objectives
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis:
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
  • 1.9.2. List of Secondary Sources
  • 1.9.3. List of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing Investment in In Vivo Cell Therapy Development
    • 3.2.1.2. Advances in Targeted Delivery Technologies
    • 3.2.1.3. Expansion of Programmable Cell Therapies for Precision Medicine
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Challenges in Achieving Precise and Targeted Delivery
    • 3.2.2.2. Regulatory Uncertainty for In Vivo Cell Therapies
  • 3.2.3. Market Opportunities Analysis
  • 3.2.4. Market Challenges Analysis
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTLE Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Economic landscape
    • 3.3.2.5. Legal landscape

Chapter 4. Therapeutic Cell Type Business Analysis

• 4.1. Segment Dashboard
• 4.2. In Vivo Cell Therapy Market: Therapeutic Cell Type Movement Analysis
  • 4.2.1. T Cells
  • 4.2.2. T Cells Market, 2021 - 2033 (USD Million)
  • 4.2.3. NK Cells
  • 4.2.4. NK Cells Kits Market, 2021 - 2033 (USD Million)
  • 4.2.5. Myeloid Cells
  • 4.2.6. Myeloid Cells Market, 2021 - 2033 (USD Million)
• 4.3. Other Immune Cells
  • 4.3.1. Other Immune Cells Market, 2021 - 2033 (USD Million)

Chapter 5. Therapeutic Application Business Analysis

• 5.1. Segment Dashboard
• 5.2. In Vivo Cell Therapy Market: Therapeutic Application Movement Analysis
• 5.3. Hematological Malignancies
  • 5.3.1. Hematological Malignancies Market, 2021 - 2033 (USD Million)
• 5.4. Solid Tumors
  • 5.4.1. Solid Tumors Market, 2021 - 2033 (USD Million)
• 5.5. Autoimmune Diseases
  • 5.5.1. Autoimmune Diseases Market, 2021 - 2033 (USD Million)
• 5.6. Infectious Diseases
  • 5.6.1. Infectious Diseases Market, 2021 - 2033 (USD Million)
• 5.7. Other Therapeutic Applications
  • 5.7.1. Other Therapeutic Applications Market, 2021 - 2033 (USD Million)

Chapter 6. In Vivo Cell-Engineering Business Analysis

• 6.1. Segment Dashboard
• 6.2. In Vivo Cell Therapy Market: In Vivo Cell-Engineering Movement Analysis
• 6.3. Receptor Engineering
  • 6.3.1. Receptor Engineering Market, 2021 - 2033 (USD Million)
• 6.4. Gene Editing & Gene Modification
  • 6.4.1. Gene Editing & Gene Modification Market, 2021 - 2033 (USD Million)
• 6.5. Transient Genetic Programming
  • 6.5.1. Transient Genetic Programming Market, 2021 - 2033 (USD Million)
• 6.6. Other Cell-Engineering Approaches
  • 6.6.1. Other Cell-Engineering Approaches Market, 2021 - 2033 (USD Million)

Chapter 7. Delivery Modality Business Analysis

• 7.1. Segment Dashboard
• 7.2. In Vivo Cell Therapy Market: Delivery Modality Movement Analysis
• 7.3. Viral Vector-based
  • 7.3.1. Viral Vector-based Market, 2021 - 2033 (USD Million)
• 7.4. Lipid Nanoparticle-based
  • 7.4.1. Lipid Nanoparticle-based Market, 2021 - 2033 (USD Million)
• 7.5. Other Non-viral Delivery Systems
  • 7.5.1. Other Non-viral Delivery Systems Market, 2021 - 2033 (USD Million)

Chapter 8. Regional Business Analysis

• 8.1. In Vivo Cell Therapy Market Share By Region, 2025 & 2033
• 8.2. North America
  • 8.2.1. North America In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
  • 8.2.2. U.S.
    • 8.2.2.1. Key Country Dynamics
    • 8.2.2.2. Competitive Scenario
    • 8.2.2.3. Regulatory Framework
    • 8.2.2.4. U.S. In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
  • 8.2.3. Canada
    • 8.2.3.1. Key Country Dynamics
    • 8.2.3.2. Competitive Scenario
    • 8.2.3.3. Regulatory Framework
    • 8.2.3.4. Canada In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
  • 8.2.4. Mexico
    • 8.2.4.1. Key Country Dynamics
    • 8.2.4.2. Competitive Scenario
    • 8.2.4.3. Regulatory Framework
    • 8.2.4.4. Mexico In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
• 8.3. Europe
  • 8.3.1. Europe In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
  • 8.3.2. UK
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. UK In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
  • 8.3.3. Germany
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Germany In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
  • 8.3.4. France
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. France In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
  • 8.3.5. Italy
    • 8.3.5.1. Key Country Dynamics
    • 8.3.5.2. Competitive Scenario
    • 8.3.5.3. Regulatory Framework
    • 8.3.5.4. Italy In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
  • 8.3.6. Spain
    • 8.3.6.1. Key Country Dynamics
    • 8.3.6.2. Competitive Scenario
    • 8.3.6.3. Regulatory Framework
    • 8.3.6.4. Spain In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
  • 8.3.7. Denmark
    • 8.3.7.1. Key Country Dynamics
    • 8.3.7.2. Competitive Scenario
    • 8.3.7.3. Regulatory Framework
    • 8.3.7.4. Denmark In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
  • 8.3.8. Sweden
    • 8.3.8.1. Key Country Dynamics
    • 8.3.8.2. Competitive Scenario
    • 8.3.8.3. Regulatory Framework
    • 8.3.8.4. Sweden In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
  • 8.3.9. Norway
    • 8.3.9.1. Key Country Dynamics
    • 8.3.9.2. Competitive Scenario
    • 8.3.9.3. Regulatory Framework
    • 8.3.9.4. Norway In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
• 8.4. Asia Pacific
  • 8.4.1. Asia Pacific In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
  • 8.4.2. Japan
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Japan In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
  • 8.4.3. China
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. China In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
  • 8.4.4. India
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. India In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
  • 8.4.5. Australia
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Australia In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
  • 8.4.6. Thailand
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Thailand In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
  • 8.4.7. South Korea
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. South Korea In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
• 8.5. Latin America
  • 8.5.1. Latin America In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
  • 8.5.2. Brazil
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Brazil In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
  • 8.5.3. Argentina
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Argentina In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
• 8.6. MEA
  • 8.6.1. MEA In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
  • 8.6.2. South Africa
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. South Africa In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
  • 8.6.3. Saudi Arabia
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Saudi Arabia In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
  • 8.6.4. UAE
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Competitive Scenario
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. UAE In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)
  • 8.6.5. Kuwait
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Competitive Scenario
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Kuwait In Vivo Cell Therapy Market, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Company Market Share/ Position Analysis, 2025
• 9.3. Strategy Mapping
• 9.4. Company Profiles/Listing
  • 9.4.1. Gilead Sciences, Inc.
    • 9.4.1.1. Overview
    • 9.4.1.2. Financial Performance
    • 9.4.1.3. Product Benchmarking
    • 9.4.1.4. Strategic Initiatives
  • 9.4.2. Legend Biotech
    • 9.4.2.1. Overview
    • 9.4.2.2. Financial Performance
    • 9.4.2.3. Product Benchmarking
    • 9.4.2.4. Strategic Initiatives
  • 9.4.3. Eli Lilly and Company
    • 9.4.3.1. Overview
    • 9.4.3.2. Financial Performance
    • 9.4.3.3. Product Benchmarking
    • 9.4.3.4. Strategic Initiatives
  • 9.4.4. CRISPR Therapeutics
    • 9.4.4.1. Overview
    • 9.4.4.2. Financial Performance
    • 9.4.4.3. Product Benchmarking
    • 9.4.4.4. Strategic Initiatives
  • 9.4.5. AbbVie Inc.
    • 9.4.5.1. Overview
    • 9.4.5.2. Financial Performance
    • 9.4.5.3. Product Benchmarking
    • 9.4.5.4. Strategic Initiatives
  • 9.4.6. Umoja Biopharma
    • 9.4.6.1. Overview
    • 9.4.6.2. Financial Performance
    • 9.4.6.3. Product Benchmarking
    • 9.4.6.4. Strategic Initiatives
  • 9.4.7. Ensoma, Inc.
    • 9.4.7.1. Overview
    • 9.4.7.2. Financial Performance
    • 9.4.7.3. Product Benchmarking
    • 9.4.7.4. Strategic Initiatives
  • 9.4.8. Intellia Therapeutics, Inc.
    • 9.4.8.1. Overview
    • 9.4.8.2. Financial Performance
    • 9.4.8.3. Product Benchmarking
    • 9.4.8.4. Strategic Initiatives
  • 9.4.9. Tessera Therapeutics
    • 9.4.9.1. Overview
    • 9.4.9.2. Financial Performance
    • 9.4.9.3. Product Benchmarking
    • 9.4.9.4. Strategic Initiatives
  • 9.4.10. AstraZeneca
    • 9.4.10.1. Overview
    • 9.4.10.2. Financial Performance
    • 9.4.10.3. Product Benchmarking
    • 9.4.10.4. Strategic Initiatives
  • 9.4.11. Johnson & Johnson
    • 9.4.11.1. Overview
    • 9.4.11.2. Financial Performance
    • 9.4.11.3. Product Benchmarking
    • 9.4.11.4. Strategic Initiatives
  • 9.4.12. Valerio Therapeutics
    • 9.4.12.1. Overview
    • 9.4.12.2. Financial Performance
    • 9.4.12.3. Product Benchmarking
    • 9.4.12.4. Strategic Initiatives